Press Release – October 2025

Resuscitec's CARL® Wins Prestigious Prix Galien USA 2025 Award

Back2life with Resuscitec's CARL® Groundbreaking ECPR Technology

October 30, 2025

Resuscitec GmbH is introducing advanced medical technology that redefines the boundaries of emergency care. The company's CARL® ECPR Technology - developed and engineered as a highly efficient Extracorporeal Cardiopulmonary Resuscitation Platform - has been awarded the Prix Galien USA 2025 Award in the category "Best Startup", widely regarded as the "Nobel Prize of biopharmaceutical research".

Prix Galien USA 2025 Award Winner

The CARL® ECPR Technoloy's winning of the Prix Galien USA 2025 Award in the "Best Startup" category underscores its potential to transform global health. Resuscitec prevailed against over 50 other nominated companies from 15 countries. The awards ceremony was held on October 30, 2025, at the American Museum of Natural History in New York City, celebrating innovations that significantly improve human health.

A New Standard in Cardiac Arrest Survival

The Resuscitec CARL® Technology temporarily takes over the function of the heart and lungs after a sudden cardiac arrest. It maintains blood circulation and gas exchange and enables physiologically based therapy until the patient's own cardiovascular function can be restored.

The CE marked technology has been used so far very successfully in over 750 clinical cases in Europe. Especially In the highly challenging group of patients with acute cardiac arrest, survival rates of over 50% were achieved, and around 80% of survivors showed no permanent brain damage – compared to less than 10% with conventional resuscitation such as chest compressions and defibrillation.

With CARL® currently deployed in numerous European countries and some GCC countries in emergency rooms, cardiac units, ambulances, and rescue helicopters, Resuscitec is seeking FDA approval for the technology.

Innovation in Action

Physiologically guided ECPR using CARL® represents the next frontier in resuscitation. By circulating blood through an external circuit, it sustains life and organ preservation during critical moments when conventional methods fall short. This technology was pioneered by an interdisciplinary team led by Prof. Dr. Georg Trummer and Prof. Dr. Christoph Benk, combining expertise from emergency medicine and medical engineering. "At Resuscitec our mission is to give people a second chance to

have a normal life after they have technically “died”. This is both a great privilege and a huge responsibility for our team,” said Prof. Trummer.

Dr. Tom Lines, Resuscitec’s Chief Scientific Officer, is spearheading the next phase of development, focusing on lysis and plasma expansion technologies to further enhance survival outcomes.

Expanding Horizons

Resuscitec is actively collaborating with Walter Reed National Military Medical Center to adapt the CARL® ECPR Technology for military use in preservation of life, resuscitation and reperfusion after massive blood loss or exsanguination. Further fields of research include oncology and organ preservation for transplantation.

About Resuscitec

Resuscitec is a medical technology company based in Freiburg in Germany that develops and manufactures technologies which can significantly improve survival rates after cardiac arrest compared to current treatment standards, enable neurologically intact survival, and open up new perspectives in emergency medicine.

www. resuscitec.com

Press Contact
Resuscitec Corp.
7200 Wisconsin Ave, Suite 500
Bethesda MD 20814
United States
press@resuscitec.de